These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 11695504)

  • 21. Development of reference ranges in elite athletes for markers of altered erythropoiesis.
    Sharpe K; Hopkins W; Emslie KR; Howe C; Trout GJ; Kazlauskas R; Ashenden MJ; Gore CJ; Parisotto R; Hahn AG
    Haematologica; 2002 Dec; 87(12):1248-57. PubMed ID: 12495898
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proposed therapeutic algorithm for the treatment of anemia of chronic renal failure in pre-dialysis patients with low dose once weekly subcutaneous r-HuEPO. Multicenter Study Group, Israel.
    Yagil Y
    Isr J Med Sci; 1997 Jan; 33(1):36-44. PubMed ID: 9203516
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Procedures for monitoring recombinant erythropoietin and analogs in doping.
    Lamon S; Robinson N; Saugy M
    Endocrinol Metab Clin North Am; 2010 Mar; 39(1):141-54, x. PubMed ID: 20122455
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The biochemistry of drugs and doping methods used to enhance aerobic sport performance.
    Cooper CE
    Essays Biochem; 2008; 44():63-83. PubMed ID: 18384283
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant human erythropoietin stimulates erythropoiesis and reduces erythrocyte transfusions in very low birth weight preterm infants.
    Shannon KM; Keith JF; Mentzer WC; Ehrenkranz RA; Brown MS; Widness JA; Gleason CA; Bifano EM; Millard DD; Davis CB
    Pediatrics; 1995 Jan; 95(1):1-8. PubMed ID: 7770284
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Doping in endurance sports. Survey of individual [Hb] levels can expose doping].
    Ekblom B; Holmberg HC; Eriksson K
    Lakartidningen; 2001 Nov; 98(48):5490-2, 5495-6. PubMed ID: 11769364
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-dose recombinant human erythropoietin for treatment of anemia in myelodysplastic syndromes and paroxysmal nocturnal hemoglobinuria: a pilot study.
    Stebler C; Tichelli A; Dazzi H; Gratwohl A; Nissen C; Speck B
    Exp Hematol; 1990 Dec; 18(11):1204-8. PubMed ID: 2226680
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recombinant human erythropoietin in anemia of prematurity.
    Whitehall JS; Patole SK; Campbell P
    Indian Pediatr; 1999 Jan; 36(1):17-27. PubMed ID: 10709119
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of recombinant human erythropoietin for management of anemia in dogs and cats with renal failure.
    Cowgill LD; James KM; Levy JK; Browne JK; Miller A; Lobingier RT; Egrie JC
    J Am Vet Med Assoc; 1998 Feb; 212(4):521-8. PubMed ID: 9491159
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Haemostatic aspects of recombinant human erythropoietin in colorectal surgery.
    Poulsen KA; Qvist N; Winther K; Boesby S
    Eur J Surg; 1998 Mar; 164(3):211-5. PubMed ID: 9562282
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Blood boosting today].
    Audran M; Varlet-Marie E
    Bull Acad Natl Med; 2004; 188(6):945-53. PubMed ID: 15651424
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects.
    Cheung WK; Goon BL; Guilfoyle MC; Wacholtz MC
    Clin Pharmacol Ther; 1998 Oct; 64(4):412-23. PubMed ID: 9797798
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Strengths and weaknesses of established indirect models to detect recombinant human erythropoietin abuse on blood samples collected 48-hr post administration.
    Connes P; Caillaud C; Simar D; Villard S; Sicart MT; Audran M
    Haematologica; 2004 Jul; 89(7):891-2. PubMed ID: 15257956
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The treatment of anemia of hemodialysis patients using recombinant human erythropoietin: comparison between intravenous and subcutaneous administration].
    Zehnder C; Blumberg A
    Schweiz Med Wochenschr; 1990 Feb; 120(7):217-20. PubMed ID: 2309110
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic-pharmacodynamic modelling of recombinant human erythropoietin in athletes.
    Varlet-Marie E; Gaudard A; Audran M; Gomeni R; Bressolle F
    Int J Sports Med; 2003 May; 24(4):252-7. PubMed ID: 12784166
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased hemoglobin mass and VO2max with 10 h nightly simulated altitude at 3000 m.
    Neya M; Enoki T; Ohiwa N; Kawahara T; Gore CJ
    Int J Sports Physiol Perform; 2013 Jul; 8(4):366-72. PubMed ID: 23118056
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intermittent hypoxia exposure in a hypobaric chamber and erythropoietin abuse interpretation.
    Abellan R; Ventura R; Remacha AF; Rodríguez FA; Pascual JA; Segura J
    J Sports Sci; 2007 Sep; 25(11):1241-50. PubMed ID: 17654236
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Altitude training causes haematological fluctuations with relevance for the Athlete Biological Passport.
    Bonne TC; Lundby C; Lundby AK; Sander M; Bejder J; Nordsborg NB
    Drug Test Anal; 2015 Aug; 7(8):655-62. PubMed ID: 25545030
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Pharma-clinics. Doping with erythropoietin or the misuse of therapeutic advances].
    Scheen AJ
    Rev Med Liege; 1998 Aug; 53(8):499-502. PubMed ID: 9810213
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Altitude Training and Recombinant Human Erythropoietin: Considerations for Doping Detection.
    Sutehall S; Muniz-Pardos B; Lima G; Wang G; Malinsky FR; Bosch A; Zelenkova I; Tanisawa K; Pigozzi F; Borrione P; Pitsiladis Y
    Curr Sports Med Rep; 2019 Apr; 18(4):97-104. PubMed ID: 30969231
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.